Grant: Master's Award: Canada Graduate Scholarships
Université Laval
$17,500.00
Predictive Aspect of Optimized Bone Marrow Dosimetry on Hematological Toxicity Induced by Personalized PRRT for Neuroendocrine Tumors
FY 2020-21
Summary
Neuroendocrine tumors (NETs) are a family of tumors originating in the diffuse neuroendocrine system. Even though most patients develop a generalized form of this condition, the presence of somatostatin receptors on their surface allows the use of treatments specifically targeting it. One such approach, the peptide receptor radionuclide therapy (PRRT), can reduce its symptoms and its progression. The most used drug for PRRT is 177Lu-octreotate. It is a molecule targeting neuroendocrine tumors, namely the somatostatin analogue Octreotate, to which a Lutetium-177 atom is added. This atom is radioactive and damages tumor cells. To limit treatment toxicity, the same activity is administered for every patient every 2 months for 4 cycles. However, most recent studies have shown that severe toxicity occurs in only 10% of patients. In this context, an innovative research protocol aimed at personalizing injected activities (P-PRRT) was developed at the CHU de Québec-Université Laval. This protocol aims to adjust the drug dosage according to the images acquired after each treatment. These images allow the medication to be properly adjusted according to renal toxicity. However, the adjustment of doses to consider blood toxicity is not optimal. Indeed, the current method is imprecise and does not allow to predict this toxicity from imaging. We believe that we will improve the prediction of blood cells toxicity by improving the accuracy of the method currently used. This improvement will allow the adjustment of doses according to the patient's blood sensitivity. Another part of the research project is to make P-PRRT more accessible. Our automated algorithm will make it easier for clinicians to use images, which could lead to a widespread use of P-PRRT in clinical settings.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449537
Name
Forget Vincent G
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Predictive Aspect of Optimized Bone Marrow Dosimetry on Hematological Toxicity Induced by Personalized PRRT for Neuroendocrine Tumors
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Imagerie Médicale; Médecine Nucléaire; Personnalisation; Radiothérapie Interne; Thérapie Radiopeptidique; Toxicité Hématologique; Tumeurs Neuroendocrines; Évolution Et Traitement Des Maladies
Abstract
Neuroendocrine tumors (NETs) are a family of tumors originating in the diffuse neuroendocrine system. Even though most patients develop a generalized form of this condition, the presence of somatostatin receptors on their surface allows the use of treatments specifically targeting it. One such approach, the peptide receptor radionuclide therapy (PRRT), can reduce its symptoms and its progression. The most used drug for PRRT is <sup>177</sup>Lu-octreotate. It is a molecule targeting neuroendocrine tumors, namely the somatostatin analogue Octreotate, to which a Lutetium-177 atom is added. This atom is radioactive and damages tumor cells. To limit treatment toxicity, the same activity is administered for every patient every 2 months for 4 cycles. However, most recent studies have shown that severe toxicity occurs in only 10% of patients. In this context, an innovative research protocol aimed at personalizing injected activities (P-PRRT) was developed at the CHU de Québec-Université Laval. This protocol aims to adjust the drug dosage according to the images acquired after each treatment. These images allow the medication to be properly adjusted according to renal toxicity. However, the adjustment of doses to consider blood toxicity is not optimal. Indeed, the current method is imprecise and does not allow to predict this toxicity from imaging. We believe that we will improve the prediction of blood cells toxicity by improving the accuracy of the method currently used. This improvement will allow the adjustment of doses according to the patient's blood sensitivity. Another part of the research project is to make P-PRRT more accessible. Our automated algorithm will make it easier for clinicians to use images, which could lead to a widespread use of P-PRRT in clinical settings.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Forget, Vincent G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~